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ABSTRACT
Non-deletion Hereditary Persistence of Fetal Hemoglobin (HPFH) is Xharact rized by great
elevation of the synthesis, in adult age, of fetal hemoIobin (HbF) of either the 'y or Yy type. Strong
genetic evidence indicates point mutations in the -y - or A
-y -globin promoter as responsible for
overexpression of the mutated gene. Here we report that a 13 nucleotides deletion in the CCAAT box
region of the A -y -globin promoter, associated with greater than 100 fold overexpression of the gene,
abolishes the in vitro binding of the ubiquitous factors CP1 and CDP (CCAAT displacement protein) and
of the erythroid specHifc protein NFE3. Loss of NFE3 binding is consistent with a similar effect of the -1 17
G -A HPFH mutation, suggesting a possible role of NFE3 as a negatively acting factor. In addition, loss
of CDP binding indicates that this alteration might also contribute to the HPFH phenotype in this
particular case, suggesting possible heterogeneity of the mechanisms causing HPFH.
INTRODUCTION
Hereditary Persistence of Fetal Hemoglobin (HPFH) is a clinically benign condition characterized
by the continued expression in adult life of one, or both, of the duplicated y -globin genes which are
normally expressed at significant levels in the fetal period only (1,2). Large deletions involving the adult
6- and f3-globin genes (sometimes together with the fetal A 'y -globin gene) are responsible for a
subclass of HPFH, in which both 'y -globin genes in cis to the deletion are usually kept active
(Gly
-Y -HPFH Gy Apy-thalassemia; G y -i3thalassemia in those cases in which the A 'y -gene is
included in the deletion); on the other hand, point mutations in the promoter of the singly overexpressed
A
^j - or G 'y -globin gene have been consistently reported in a subclass of HPFH not detectable
associated with deletions (3-15). A causal relationship of these mutations to the HPFH phenotype is
strongly, though indirectly, supported by two types of genetic evidence: - the same mutation is present
in HPFH 'y -globin genes of patients of dffferent ethnic origins (reviewed in refs. 12,14) Indicating
independent occurrence of the mutation; this point is strengthened by haplotype analysis and by the
observation of the same mutation (-175 T-C) in either the G
-y or A -y -globin gene in different HPFH
patients (12,13-15); - the mutation thought to be responsible for HPFH has never been detected, in
population analyses, in normal individuals (4,10-1 1).
The molecular mechanisms underlying the greatly elevated expression of'y -globin genes In HPFH
are unknown. Recently, the analysis of the effects of two HPFH mutations (-175 T-C and -117 G -A) on
the ability of nuclear erythrold proteins to bind to 'y -globin promoter fragments has Indicated that
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several proteins may be affected simultaneously, and suggested that the HPFH phenotype might be the
result of Increased binding of activator proteins as well as of loss of binding of inhibitor proteins (16-20).
However, the complex effect of the mutation raises the question which of the observed alterations in
binding is responsible for HPFH, and by which mechanism (loss of inhibition rather than activation). In
order to get further insight into this problem, we have now studied a newly discovered A y -HPFH (21),
characterized by great elevation of HbF (- 30% in heterozygotes), that is associated with a 13
nucleotides deletion in the CCAAT box region of the A'y-globin promoter.
Here we show that loss of binding of the erythroid factor NFE3 is the only common effect of the
-117 G -A and 13 nt. deletion HPFH's; in addition, we demonstrate complete loss of binding of the
ubiquitous protein CDP (22). The possible significance of altered binding of NFE3, CDP and of the
erythroid specific protein NFE1 (16,17) In this and other types of HPFH is discussed.
MATERIALS AND METHODS
Preparation of nuclear extracts
Nuclear extracts were prepared exactly as described by Dignam et al. (23) from exponentially
growing K562 cells (24). Some extracts were prepared with the modifications (ammonium sulphate
precipitation followed by dialysis) described by Superti-Furga et al. (17); the latter extracts were used for
studying CDP binding (Figure 5).
Ollaonucleotides
Oligonucleotides were prepared and annealed according to ref. 17. The sequences of these
oligonucleotides are shown In Figure 2 or indicated in the papers quoted in the text.
The human -globin enhancer oligonucleotide (see Figure 3) has the sequence (top
strand only is indicated):
5' GTCTTATTACCCTATCATAGGCCCACCCCAAATGGAAGTCCCATTCTTCC 3'; this oligonucleotide
contains an NFE1 binding (underlined) site (16,25) and at least one CPI binding site (25; R. M. and
S. O.; unpublished data).
The human P-globin enhancer oligonucleotide (see Figure 5) has the sequence
5' CAGGGACATGATAAGGGAGCCAA 3'.
Electrophoretic mobility shift assay (26)
Binding reactions and electrophoretic runs were carried out essentially according to ref. 24;
briefly, the standard assay contained (in a 20 pi reaction): 0.1-0.2 ngs of 32 P-labelled oligonucleotide,
3-9 pgs of nuclear protein, 3pgs of poly (di-dC), 2 pgs of bovine serum albumin In a buffer consisting of
4 mM spermidine, 50 mM NaCI, 1 mM EDTA, 10 mM Tris HCI pH 7.9, 1mM DDT, 0.5 mM PMSF.
Unlabelled competitor DNAs were as specifled in Legend to Figures. For optimal detection of NFE3, the
higher amounts (6-9 pgs) of nuclear proteins were used. Incubation was at 200C for 30'. Gel
electrophoresis was in 5% acrylamide gels in 50 mM Tris borate pH 8.2. Experiments shown In Figure 5
were performed according to conditions specially modified to optimnize detection of both NFE1 and CDP
(17).
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Figure 1
Promoter structure of the y -globin genes and HPFH mutations in this region. Boxes Indicate various
nuclear protein binding sites; the TGA motifs (open half boxes) and the CCAAT box are essential for
CDP binding. CP1 binds to the sequence CCAAT, NFE1 to the consensus GAT/CAG, present at two
sites, proximal and distal.
Transfection
2x107 cells In 0.8 ml of phosphate buffered saline were transfected by electroporation at 400 Volts,
400 pF, In the presence of 30 pgs of CAT reporter plasmids (27) driven by normal or mutant Py -globin
promoters (28). Cells were recovered two days after transfection and lysed; CAT activity was assayed
according to refs. 27,28.
RESULTS
The bindina site of NFE-3 overlaDs with the distal CCAAT box
At least four dfflerent proteins bind in vitro to the human y -globin promoter CCAAT box region
(Figure 1). Two of these proteins are ubiquitously present in animal cells: CP1, a transcriptional activator
(29) and CDP, a putative repressor (22). The other two proteins are erythroid speciflc and will be referred
to as NFE1 (17) and NFE3 (see Figure 7 in ref. 16) respectively (NFE3 was referred to as NFE2 in ref. 19;
it is called here NFE3 to avoid confusion with the different factor NFE2 described by Mignotte et al. (30).
Previous experiments (16) had shown that the -1 17 G-A substitution causing Greek HPFH almost
completely abolishes NFE3 binding; to better locate the binding site for the this protein, we tested
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Figure 2
Sequence requirements for binding of NFE3 to the 'y -globin CCMT region. Oligonucleotides containing
the mutations indicated in the lower part of the figure were annealed and used for eiectrophoretic
mobUity shift analysis. Oligonucleotides used are Indicated by their respective numbers on the top of the
figure. The effect of the mutations on NFE3 binding was evaluated densitometrically by reference to
bands Cl and/or C3. For oligonucleotide 2 the decrease was 40-60%, for oligonucleotides 3 and 4
50-80%, for oligonucleotides 5 and 6-90 and -80% (4 experiments).
Lower part: the distal CCAAT box and the NFE1 binding sequence are underlined; GCCTTG motifs and
their polarity are indicated by arrows.
6684
--------------A----------------------------------------------------------------
--------------c----------------------------------------------------------------
-
00
Nucleic Acids Research
mutant oligonucleotides for NFE-3 binding by gel shift assays (16,24,26). With the normal 27 mer used
(Figure 2) three bands are detected: Cl, C2 and C3 (16). CO is generated by interaction with a CCAAT
binding protein (CP1) and C2 by interaction with NFE3; C3 is known to be due to unspecific binding.
With the exception of the G_-A change at position -122, all point mutations from positions -122 to -116
significantly (50-80%) decrease band C2 (Figure 2). These data identify the GCCTTG motif (-122 to -117)
as an important part of the recognition element for NFE3; this motif is repeated twice 5' and twice 3' to
the CCAAT box (the most 3' repeat is in reverse orientation relative to the other ones).
The comparison of the binding of oligonucleotides of different lengths indicates that the two
GCCTTG motifs immediately flanking the CCAAT box are important for NFE-3 binding (see lack of
binding of oligonucleotides 9 and 10 and the -3-fold increased binding of oligonucleotide 7, -109 G-A);
on the other hand, the first and fourth GCCTTG motifs are not essential as oligonucleotide 8, lacking the
first motif, and the normal 27 mer, lacking the fourth one, bind as well as the normal 42 mer (Figure 2
and data not shown). Of the sequences comprised between the second and fourth motif, only the A at
position -116 appears to be important, as shown by the greatly decreased (-80%) binding of
oligonucleotide 6; C-T substitutions at positlons -115, 114 have only a slight effect (not shown).
Finally, although the NFE-1 core recognition element at position -104 to -98 (GACAAGG) is not
necessary for NFE-3 binding (see normal 27 mer), the observation that the -1 17 G-A substitution affects
both NFE-3 and NFE-1 binding (16,17) implies that the respective binding sites of these two proteins
afso somewhat overlap.
The HPFH- 13 nucleotide deletion in the AT -alobin oromoter abolishes the bindina of CP1 and NFE3
To evaluate the effect of the 13 nucleotide deletion associated with HPFH on binding of nuclear
proteins, we used a 42 nt. oligomer and its 29 nt. corresponding mutated version (Figure 2,
oligonucleotide 11) for gel shift assays (Figures 3A and B). This 42-mer contains the distal CCAAT box
sequence and the NFE1 and NFE3 binding sites; it generates with nuclear extracts from the erythroid
cell line K562 three different bands, migrating exactly as those generated by the normal 27 mer and
labelled in the same way. Cl corresponds to the band generated by a CCAAT box binding protein,
presumably CP1 (17), C2 is generated by interaction with NFE3 and C3 is mostly due to binding of
NFE1, as demonstrated by comigration (not shown) with complexes obtained using oligonucleotides
carrying the appropriate binding sites and by competition experiments (Figure 2, see legend for details).
Note, in addition, that the NFE1 band is somewhat contaminated by a band due to the same unspecific
binding as observed with the 27-mer (16).
The effects of the HPFH 13-nt deletion are seen both by direct binding and by competition
experiments; the deletion abolishes both CP1 and NFE3, but not NFE1 binding (Figure 3). Figure 3A,
lane 1 indicates that the HPFH 29-mer does not generate Cl and C2 while band C3 is essentially normal.
The inability of the HPFH oligomer to bind CP1 and NFE3 is confirmed by competition experiments,
showing that the unlabelled oligomer is unable to decrease bands Cl and C2 generated with labelled
42-mer (Figure 3B, lane 3); a 20-mer (Figure 2, oligonucleotide 9) lacking both the CP1 and NFE-3 sites
is equally unable to compete (Figure 3B, lane 4); under the same conditions, a control 27 mer known to
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Figure 3
Binding of K562 nuclear proteins to normal and 13 nt. HPFH deletion oligonucleotides. (A) Labelled
normal 42 mer and 13 nt. HPFH 29 mer were used for electrophoretic mobility shift analysis; lane 1
HPFH, lane 2 normal. (B) Labelled normal 42 mer was Incubated in K562 cell extracts In the presence of
excess (50-200 fold) unlabelled competitor (as indicated on the top of the figure) and analysed as above.
Competitors are wt. 42 mer, HPFH 29 mer, deleted oligonucleotide 9, wild type and -117 HPFH 27 mer
(see Figure 2), normal and -175 HPFH 'y -globin octamer region, human NFE1 binding site from(3-globin enhancer and mouse CX 1 globin oligonucleotides (16), normal and mutated 27 mer MHC-EQCCAAT box oligonucleotldes (31). Bands Cl, C2 and C3 are assigned to CP1, NFE3 and NFE1,
respectively, on the basis of comigration with bands generated by appropriate marker oligonucleotides
(not shown) and competition experiments. Briefly, band CO is competed specifically by oiigonucleotides
containing a CCAAT box capable of binding CPI or its mouse homolog NFY (31), i.e. wild type and -117
HPFH 27 mer (16,17) (lanes 5 and 6), human f3-globin enhancer (25) (lane 9) and normal (lane 11), but
not mutated (lane 12) MHC-ECa oligonucleotldes (31); note that 90-100% competition can be obtained
(not shown) with higher levels (200-fold instead of 50 fold) of competitor MHC-Ea. Band C2 is competed
only by normal, not by -117 HPFH 27 mer (16) (lanes 5 and 6). Band C3 is competed (partially, due to
comigration with an unspecific band, see lane 2) by HPFH 29 mer normal and -175 HPFH y -globin
octamer region (16), humanB3-globin enhancer (16,25) and mouse a 1-globin (16,34) oligonucleotides,
all containing a NFE-1 binding site (lanes 3,7-10).
bind both CPI and NFE-3 greatly decreases (Figure 3, lane 5) bands Cl and C2, while the -117 HPFH
27-mer (unable to bind NFE3, ref. 16) competes only against band Cl, but not C2 (Figure 3, lane 6).
The HPFH deletion does not sianiflcantlv affect NFE1 binding
The presence of an unspecific component in band C3 prevents a conclusive direct analysis of
NFE-1 binding. To circumvent this problem, we used unlabelled normal 42-mer and HPFH 29-mer in
competition experiments against labelled distal -y -globin NFE-1 binding site (-175 HPFH version, 16).
Figure 4 Indicates a very similar competition; the normal sequence appears to be at most twice as
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Figure 4
Competition of unlabelled wild type 42 mer and HPFH 29 mer for the NFE1 binding site of labelled -175
HPFH oligonucleotide. Labelled -175 HPFH oligonucleotide (16) (0.2-0.4 nanograms) was Incubated
with 5,10,20,40,80 nanograms (arrow) of unlabelled competitor in K562 cell extracts and analyzed by
elctrophoretic mobility shift experiments.
efficient as the HPFH-sequence in preventing binding to the -175 HPFH NFE-1 site. In parallel
competition experiments an unlabelled oligonucleotide corresponding to the distal NFE1 binding site
(positions -190 to -168, ref. 16) competes against the labelled oligonucleotide approximately four fold
better than normal 42-mer and HPFH 29-mer (not shown).
The HPFH deletion abolishes CDP bindina
To study CDP binding, a labelled Ball-Hpall fragment (17) from the normal and HPFH
'y-globin promoters was directly used in gel shift experiments; nuclear extract preparation and binding
conditions are optimized for detecting CDP binding according to Superti-Furga et al. (17), and differ
from those used In Figures 2-4 to detect NFE1, NFE3 and CP1 (NFE3 is not detected under these
conditions). Figure 5 shows that the CDP band (clearly identified by its disappearance upon competition
with a CDP-binding site from the histone sperm H2B gene, see ref. 22) is completely suppressed by the
HPFH deletion (compare lanes 6-8 with lane 5).
In addition, the experiments in fig. 5 confirm that the HPFH mutation leaves NFE-1 binding
essentially intact (compare lane 6 with lane 5); under these conditions, the unspecific band comigrating
with C3 and not self -competed (Figure 3) Is not seen (see lanes 3,4,7 and 9), allowing direct evaluation
of NFE-1 binding. As the fragment used in this experiment contains the proximal CCAAT box, spared by
the deletion, CP1 binding Is apparently not decreased by the HPFH deletion; actually, while the zed
band (NFE-1 plus CP1 bound to the same fragment) Is very similar using the normal and mutated
oligomers, the CPI band Is somewhat increased. This effect might be a secondary consequence of the
loss of the CDP binding site, allowing Increased reaction between CCAAT box and CPI.
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Figure 5
Electrophoretic mobility shift analysis of CDP and NFE1 binding to normal and -13 nt. deletion HPFH. A
Ball-Hpall fragment (17) from the normal or HPFH DNA was 5' terminally labelled with polynucleotlde
kynase, Incubated In K562 cell extract with excess (300 fold) competitor under conditions optimized for
CDP assays (17) and used for mobility shift analysis. Competitors are indicated on the top of the figure
as follows: CP1: CCAAT box of mouse a 1 globin (see ref. 17, Table I); NFE1: NFE1 binding site
GATAAG from the human a -globin enhancer (25; see the sequence In Materials and Methods); CDP: a
PVUII-Fokl fragment from the histone sperm H2B promoter, containing a CDP binding site and mutated
in the CCAAT box (see ref. 22, figure 5). This oligonucleotide happens to contain some NFE1 binding
sequences, and it Is thus also a competitor for NFE1. In the first lane, labelled a 1-mouse
oligonucleotide, containing a NFE1 -binding site (16,34) was used as a control. Bands are Indicated: for
complex Z (CP1 + NFE1) see ref. 17.
Functional analysis
A fragment from the promoter of the 13 nucleotlde deletion HPFH (from position -299 to +35)
was Joined by linkers to the Hind IlIl site of the CAT-reporter plasmid pSVo (27,28). This, and similarly
constructed plasmids carrying the normal or the -175 HPFH promoter sequences, were transfected by
electroporation Into K562 cells; after two days of culture, chloramphenicol acetyltransferase acthivty was
determined (27). In agreement with previous results (28,33) the -175 HPFH plasmid gave an
approximately four-fold stimulation relative to the normal control; however, the 13 nucleotides deletion
mutant was as active as the normal promoter. Thus, the loss of the binding sites for CP1, CDP and NFE3
is not reflected, in K562 cells, in Increased activity of the promoter, contrary to the in vivo data. SimNarly
negative results have been reported, in K562 and MEL cells for the -202 and -196 HPFH mutations (33);
this probably reflects the fact that these cells allow expression of endogenous or transfected -y -globin
genes, while the HPFH phenotype is observed, in vivo, in cells in which normal "y -globin genes are
almost completely repressed.
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DISCUSSION
The black HPFH 13 nucleotides deletion removes the distal CCAAT box and one of the TGA
repeats, thought to be essential for CDP binding (17), and the third GCCTTG repeat, leading to complete
loss of binding of CP1 (to the distal CCAAT box), CDP and NFE-3.
The binding of NFE3 can now be clearly discriminated from that of either CP1 or NFE1. In fact,
partial or total competition for CP1 by unlabelled nucleotides (Figure 3B, lanes 9 and 11) does not
decrease NFE3 binding; on the other hand, normal or increased binding of CP1 to the -117 HPFH
oligonucleotide (1 6,17,32; see also Figure 2) is associated with almost complete disappearance of NFE3
binding (16). Similarly, competition for NFE1 does not decrease NFE3 binding (16; see also Figure 3,
lanes 7-10); moreover, the wild type 27 mer binds NFE3, but not NFE1 (16), while che HPFH 29 mer
binds NFE1, but not NFE3 (Figure 4).
Recent attempts to understand the HPFH phenotype have focused on alterations in binding of
nuclear proteins to the mutated promoter (16,17,32,33). The -175 T- C HPFH mutation increases (four-
fold) the activity of the-y-globin promoter in transfection assays in K562 cells (28,33), by increasing (16)
or "altering" (33) the binding of NFE1 to a distal site in the -195 to -170 region; it is unclear whether this
change is relevant to the in vivo HPFH phenotype (28), but the data do suggest that NFE1 binding to the
distal site has a positive effect on 'y-globin promoter activity. Unfortunately, due to the lack of proper
human adult erythrold cell lines the -175 HPFH promoter is unique In showing a functional effect in
transfection assays (33 and present paper); at present, clues to the molecular mechanisms of HPFH can
only be obtained by comparison of binding alterations with the in vivo phenotype.
Two HPFH mutations affect the duplicated CCAAT box region: the -117 and the 13 nucleotides
deletion HPFH's. In the -117 HPFH the binding of both NFE1 and NFE3 Is greatly decreased (16,17)
while the binding of CP1 and CDP Is slightly increased (17,32); in the 13 nucleotides deletion HPFH, the
binding of CP1, CDP and NFE3, but not NFE1, is lost. Though the two mutations are located in the same
region, it Is possible that the molecular mechanisms underlying the HPFH phenotype are
heterogeneous; If this is the case, any one of the proteins (CDP,CP1 ,NFE3) whose binding Is affected by
the 13 nucleotides deletion might behave as a negatively acting factor fory -globin expression. CDP was
postulated to be such a factor on the basis of its dominant binding (versus CCAAT box binding factors)
to the sea urchin H2B histone or human -y -giobin promoters (18,22). On the other hand, If similar
mechanisms are responsible for the two types of HPFH, the loss of NFE3 binding Is the only common
alteration In both the -117 and 13 nucleotides deletion HPFH, suggesting a negatively acting role for this
protein. Continuous search for new HPFH mutations and the development of functional assays In adult-
type erythroid cells are necessary to understand the role of these proteins in HPFH.
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